Regeneron Pharmaceuticals Inc. Stock Falls 4.5%, Underperforms Peers
Dow Jones2026/09/28 20:33This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Regeneron Pharmaceuticals Inc. slid 4.5% to $752.25 on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.8% to 7,683.69 and Dow Jones Industrial Average falling 0.7% to 51,481.51.
This was the stock's fourth consecutive day of losses.
Regeneron Pharmaceuticals Inc. closed 12.5% below its 52-week high of $859.34, which the company achieved on September 3rd.
The stock underperformed when compared to some of its peers, as Amgen Inc. rose 0.8% to $418.13, Moderna Inc. fell 0.8% to $197.28, and Gilead Sciences Inc. rose 0.85% to $152.21.
Trading volume totaled 1.1 million, compared to the 50-day average of 746,021.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 28, 2026 16:33 ET (20:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Besent “Extinguishes Fire”: Rising US Treasury yields are a global phenomenon, dismisses concerns over AI bubble
U.S. Treasury Secretary Janet Yellen defended the rise in U.S. Treasury yields, stating that this increase is a global phenomenon rather than unique to the United States, and does not warrant excessive concern. She partially attributed inflationary pressures to higher oil prices caused by the Iran conflict, and expects the energy shock to subside as hostilities ease. Yellen refuted the notion of an AI bubble, arguing that investments by major tech companies are grounded in solid business logic.
Crypto prices
More
